Microbiotix, Worcester, MA, USA
www.microbiotix.com

TRANS-TRANSLATION INHIBITORS
MDR NEISSERIA GONORRHOEAE
Oral Antibiotic

Drug-resistant Neisseria gonorrhoeae (Ng) is a WHO priority pathogen and classified by the CDC as an immediate public health threat that requires urgent and aggressive action. CARB-X funding will support Microbiotix’s project to optimize and develop a series of broad-spectrum bacterial trans-translation inhibitors into a new class antibiotic for use as a single-dose oral therapy to treat sexually transmitted infections caused by multidrug-resistant Ng. Genes associated with trans-translation have been found in every bacterial genome sequenced to date; mutations in these components affect viability or virulence in a wide variety of bacteria, and are essential in Ng.

Current Development Stage: Hit-to-lead

CARB-X Investment: Initial investment of up to $2.86m with potential option payments up to $16m.

Initial CARB-X Investment Date: November 1, 2019